- Protocol Short Name and Number: Etanercept IPS, 0403
- Protocol Long Name: A Phase III, Randomized Double-Blind, Placebo Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
- Protocol (PDF)
- Informed Consent
- Frequently Asked Questions
- Key Personnel
- BMT CTN # 0403 Protocol Co-Chair: Ken Cooke, MD
- BMT CTN # 0403 Protocol Co-Chair: Greg Yanik, MD
- BMT CTN # 0403 Protocol Officer: Mary Horowitz, MD
- BMT CTN # 0403 Medical Monitor: Marcie Riches, MD
- BMT CTN # 0403 Protocol Coordinator: bmtctn@emmes.com
- Keywords: Etanercept, Enbrel, Idiopathic Pneumonia Syndrome, IPS
BMT CTN Protocol #0403 closed to patient accrual on September 14, 2011.